Immunomodulation Therapy for Urinary Tract Infections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-01

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Urinary tract infections (UTI) represent one of the most common morbidities in individuals with spinal cord injury (SCI) and reason for re-hospitalization. The consequences of recurrent UTI are a decrease in quality of life and considerable health costs. Immunomodulation therapy with UroVaxom is a very promising method for the prevention of UTI, however data in individuals with SCI are very limited. The primary objective of this pilot study is to evaluate the feasibility (recruitment rate, patient attrition, compliance, assessment procedures etc.) of a main trial. A secondary objective is to collect data for an informed sample size calculation. Furthermore, the clinical and biological changes after immunomodulation therapy will be investigated.

This is a randomized, placebo-controlled, mono-centric pilot study investigating the feasibility of a main trial regarding the effectiveness of immunomodulation with UroVaxom in the prevention of UTI and the effect on the immune system in individuals with acute SCI during primary rehabilitation. There will be two parallel groups of 12 participants each. Group allocation will be based on a block-randomization stratified according to sex. Study participants and outcome assessors will be blinded to the group allocation. The nursing staff will be unblinded and will administer the treatment and the placebo. Study participants will either receive Uro-Vaxom (one tablet / day) or an off-the-shelf placebo for 90 days. After termination of the treatment, the study participants will be followed for 12 months. Blood and urine samples will be taken before and 90 days, 6 months and 12 months after treatment start.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods)

NCT02591901

UTI Neurogenic Bladder Antibiotic Resistance

COMPLETED PHASE2

Prevention of Urinary Tract Infection (UTI) in Persons With Spinal Cord Injury (SCI)

NCT00309114

Urinary Tract Infections

COMPLETED NA

UTI Prophylaxis Using Bacterial Interference Following SCI

NCT00037921

Urinary Tract Infections

COMPLETED PHASE2

Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury

NCT03503513

Urinary Tract Infections Spinal Cord Injuries Spinal Cord Diseases +1 more

COMPLETED PHASE2/PHASE3

Incidence of Urinary Tract Infection After Urodynamic Investigation

NCT01297647

Neurogenic Bladder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injuries Urinary Tract Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immunomodulation

Lyophilized lysate of 18 E. coli strains (6 mg) for oral application. A treatment lasts 90 days (one capsule daily).

Group Type EXPERIMENTAL

Uro-Vaxom

Intervention Type DRUG

Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.

Placebo

Oral placebo tablet once daily for 90 days.

Group Type PLACEBO_COMPARATOR

Placebo oral tablet

Intervention Type DRUG

Placebo oral tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Uro-Vaxom

Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.

Intervention Type DRUG

Placebo oral tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* acute SCI (within 8 weeks after SCI)
* onset of SCI within 72h
* age from 18 to 70 years
* informed consent as documented by signature

Exclusion Criteria

* known hypersensitivity to investigational product,
* other immunomodulation therapy,
* immunosuppressant therapy,
* oncological condition or therapy,
* autoimmune diseases, nephropathy, bladder stones,
* women who are pregnant (pregnancy test) or breast feeding,
* participation in another study with an investigational drug within the 30 days preceding and during the present study

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No